Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Inogatran is a synthetic thrombin inhibitor, developed for the possible treatment and prophylaxis of venous and arterial thrombotic diseases.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 2,120.00 | |
50 mg | 8-10 weeks | $ 2,780.00 | |
100 mg | 8-10 weeks | $ 3,700.00 |
Description | Inogatran is a synthetic thrombin inhibitor, developed for the possible treatment and prophylaxis of venous and arterial thrombotic diseases. |
In vivo | Inogatran enhances vena caval blood circulation and diminishes the frequency of thrombotic occlusions in rat studies. Administered intravenously in a canine model of venous thrombosis at dosages of 0.075, 0.25, and 0.75 mg/kg, Inogatran (H-314-27) exhibits a dose-dependent augmentation in activated partial thromboplastin time (aPTT), thrombin time (TT), and prothrombin time (PT), indicative of its anticoagulant effects. This corresponds with a dose-related inhibition of thrombus formation, evidenced by extended time to occlusion (TTO) and reduced thrombus mass. |
Synonyms | H-314-27 |
Molecular Weight | 438.56 |
Formula | C21H38N6O4 |
CAS No. | 155415-08-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Inogatran 155415-08-0 Others H-314-27 inhibitor inhibit